1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Pipeline Review, H2 2020, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.
Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 23, 170, 134, 1, 14, 298, 56 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 14, 19, 1, 68 and 26 molecules, respectively.
Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionProstate Cancer - Overview
Prostate Cancer - Therapeutics Development
Prostate Cancer - Therapeutics Assessment
Prostate Cancer - Companies Involved in Therapeutics Development
Prostate Cancer - Drug Profiles
Prostate Cancer - Dormant Projects
Prostate Cancer - Discontinued Products
Prostate Cancer - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Prostate Cancer, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Prostate Cancer - Pipeline by 4D Pharma Plc, H2 2020
- Prostate Cancer - Pipeline by 4SC AG, H2 2020
- Prostate Cancer - Pipeline by Aavocyte Inc, H2 2020
- Prostate Cancer - Pipeline by AB Science SA, H2 2020
- Prostate Cancer - Pipeline by Abbisko Therapeutics Co Ltd, H2 2020
- Prostate Cancer - Pipeline by AbbVie Inc, H2 2020
- Prostate Cancer - Pipeline by Abion Inc, H2 2020
- Prostate Cancer - Pipeline by Actinium Pharmaceuticals Inc, H2 2020
- Prostate Cancer - Pipeline by Adicet Bio Inc, H2 2020
- Prostate Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2020
- Prostate Cancer - Pipeline by Advaxis Inc, H2 2020
- Prostate Cancer - Pipeline by Adze Biotechnology Inc, H2 2020
- Prostate Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2020
- Prostate Cancer - Pipeline by Affina Biotechnologies Inc, H2 2020
- Prostate Cancer - Pipeline by Agenus Inc, H2 2020
- Prostate Cancer - Pipeline by AIkido Pharma Inc, H2 2020
- Prostate Cancer - Pipeline by AIM ImmunoTech Inc, H2 2020
- Prostate Cancer - Pipeline by Akshaya Bio Inc, H2 2020
- Prostate Cancer - Pipeline by Alla Chem LLC, H2 2020
- Prostate Cancer - Pipeline by Allarity Therapeutics A/S, H2 2020
- Prostate Cancer - Pipeline by Allife Medical Science and Technology Co Ltd, H2 2020
- Prostate Cancer - Pipeline by Alligator Bioscience AB, H2 2020
- Prostate Cancer - Pipeline by Almac Discovery Ltd, H2 2020
- Prostate Cancer - Pipeline by AlphaMab Co Ltd, H2 2020
- Prostate Cancer - Pipeline by Alphamab Oncology, H2 2020
- Prostate Cancer - Pipeline by ALRISE Biosystems GmbH, H2 2020
- Prostate Cancer - Pipeline by Altay Therapeutics Inc, H2 2020
- Prostate Cancer - Pipeline by Ambrx Inc, H2 2020
- Prostate Cancer - Pipeline by American Gene Technologies International Inc, H2 2020
- Prostate Cancer - Pipeline by Amgen Inc, H2 2020
- Prostate Cancer - Pipeline by Anastasis Biotec Ltd, H2 2020
- Prostate Cancer - Pipeline by Anavex Life Sciences Corp, H2 2020
- Prostate Cancer - Pipeline by Andes Biotechnologies, H2 2020
- Prostate Cancer - Pipeline by Anew Oncology Inc, H2 2020
- Prostate Cancer - Pipeline by AnGes Inc, H2 2020
- Prostate Cancer - Pipeline by Antapodia Therapeutics Inc, H2 2020
- Prostate Cancer - Pipeline by AntiCancer Inc, H2 2020
- Prostate Cancer - Pipeline by Antikor Biopharma Ltd, H2 2020
- Prostate Cancer - Pipeline by Apcure SAS, H2 2020
- Prostate Cancer - Pipeline by Apexian Pharmaceuticals Inc, H2 2020
- Prostate Cancer - Pipeline by Aphios Corp, H2 2020
- Prostate Cancer - Pipeline by Apidel SA, H2 2020
- Prostate Cancer - Pipeline by APIM Therapeutics AS, H2 2020
- Prostate Cancer - Pipeline by Aprilbio Co Ltd, H2 2020
- Prostate Cancer - Pipeline by Aqualung Therapeutics Corp, H2 2020
- Prostate Cancer - Pipeline by Aranda Pharma Ltd, H2 2020
- Prostate Cancer - Pipeline by Arch Oncology Inc, H2 2020
- Prostate Cancer - Pipeline by Arcus Biosciences Inc, H2 2020
- Prostate Cancer - Pipeline by Ariz Precision Medicine Inc, H2 2020
- Prostate Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2020
- Prostate Cancer - Pipeline by Artelo Biosciences Inc, H2 2020
- Prostate Cancer - Pipeline by Arvinas Inc, H2 2020
- Prostate Cancer - Pipeline by Ascelia Pharma AB, H2 2020
- Prostate Cancer - Pipeline by Asdera LLC, H2 2020
- Prostate Cancer - Pipeline by Asieris Pharmaceuticals Co Ltd, H2 2020
- Prostate Cancer - Pipeline by AskAt Inc, H2 2020
- Prostate Cancer - Pipeline by AstraZeneca Plc, H2 2020
- Prostate Cancer - Pipeline by Athenex Inc, H2 2020
- Prostate Cancer - Pipeline by AUM Biosciences Pte Ltd, H2 2020
- Prostate Cancer - Pipeline by Auransa Inc, H2 2020
- Prostate Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2020
- Prostate Cancer - Pipeline by Autolus Therapeutics Plc, H2 2020
- Prostate Cancer - Pipeline by Avican Inc, H2 2020
- Prostate Cancer - Pipeline by Avivia BV, H2 2020
- Prostate Cancer - Pipeline by B3 Bio Inc, H2 2020
- Prostate Cancer - Pipeline by Bantam Pharmaceutical LLC, H2 2020
- Prostate Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2020
- Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2020
- Prostate Cancer - Pipeline by Bayer AG, H2 2020
- Prostate Cancer - Pipeline by BeiGene Ltd, H2 2020
- Prostate Cancer - Pipeline by Beijing Konruns Pharmaceutical Co Ltd, H2 2020
- Prostate Cancer - Pipeline by Bellicum Pharmaceuticals Inc, H2 2020
- Prostate Cancer - Pipeline by Better Life Pharmaceuticals Inc, H2 2020
- Prostate Cancer - Pipeline by Momotaro-Gene Inc, H2 2020
- Prostate Cancer - Pipeline by Multitude therapeutics Inc, H2 2020
- Prostate Cancer - Pipeline by Mustang Bio Inc, H2 2020
List of Figures
- Number of Products under Development for Prostate Cancer, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Pharma Plc
- 4SC AG
- Aavocyte Inc
- AB Science SA
- Abbisko Therapeutics Co Ltd
- AbbVie Inc
- Abion Inc
- Actinium Pharmaceuticals Inc
- Adicet Bio Inc
- Advanced Accelerator Applications SA
- Advaxis Inc
- Adze Biotechnology Inc
- Aeglea BioTherapeutics Inc
- Affina Biotechnologies Inc
- Agenus Inc
- AIkido Pharma Inc
- AIM ImmunoTech Inc
- Akshaya Bio Inc
- Alla Chem LLC
- Allarity Therapeutics A/S
- Allife Medical Science and Technology Co Ltd
- Alligator Bioscience AB
- Almac Discovery Ltd
- AlphaMab Co Ltd
- Alphamab Oncology
- ALRISE Biosystems GmbH
- Altay Therapeutics Inc
- Ambrx Inc
- American Gene Technologies International Inc
- Amgen Inc
- Anastasis Biotec Ltd
- Anavex Life Sciences Corp
- Andes Biotechnologies
- Anew Oncology Inc
- AnGes Inc
- Antapodia Therapeutics Inc
- AntiCancer Inc
- Antikor Biopharma Ltd
- Apcure SAS
- Apexian Pharmaceuticals Inc
- Aphios Corp
- Apidel SA
- APIM Therapeutics AS
- Aprilbio Co Ltd
- Aqualung Therapeutics Corp
- Aranda Pharma Ltd
- Arch Oncology Inc
- Arcus Biosciences Inc
- Ariz Precision Medicine Inc
- Arrien Pharmaceuticals LLC
- Artelo Biosciences Inc
- Arvinas Inc
- Ascelia Pharma AB
- Asdera LLC
- Asieris Pharmaceuticals Co Ltd
- AskAt Inc
- AstraZeneca Plc
- Athenex Inc
- AUM Biosciences Pte Ltd
- Auransa Inc
- Aurigene Discovery Technologies Ltd
- Autolus Therapeutics Plc
- Avican Inc
- Avivia BV
- B3 Bio Inc
- Bantam Pharmaceutical LLC
- Basilea Pharmaceutica Ltd
- Bavarian Nordic A/S
- Bayer AG
- BeiGene Ltd
- Beijing Konruns Pharmaceutical Co Ltd
- Bellicum Pharmaceuticals Inc
- Better Life Pharmaceuticals Inc
- Bexion Pharmaceuticals LLC
- BeyondSpring Inc
- Bicycle Therapeutics Plc
- Bio-Cancer Treatment International Ltd
- BioAtla LLC
- BioCurity Pharmaceuticals Inc
- BioEclipse Therapeutics Inc
- Biokine Therapeutics Ltd
- BioNTech SE
- Biopep Solutions Inc
- Biosceptre International Ltd
- Biosion Inc
- BioVec Pharma Inc
- Bioven Group
- BioXcel Therapeutics Inc
- bluebird bio Inc
- Boehringer Ingelheim International GmbH
- BriaCell Therapeutics Corp
- Bristol-Myers Squibb Co
- Bukwang Pharmaceutical Co Ltd
- Calidi Biotherapeutics Inc
- Calidum Inc
- Camurus AB
- Can-Fite BioPharma Ltd
- CanBas Co Ltd
- Cancer Targeted Technology LLC
- Candel Therapeutics
- Canget BioTekpharma LLC
- Cardiff Oncology Inc
- Carrick Therapeutics UK Ltd
- CAS-Lamvac Biotech Co Ltd
- Cassiopea SpA
- Cellbion Co Ltd
- CellCentric Ltd
- Celldex Therapeutics Inc
- Cellestia Biotech AG
- Cellid Co Ltd
- Cellmid Ltd
- Cello Therapeutics Inc
- Cells for Cells SA
- Celprogen Inc
- Celtek Bioscience LLC
- ChemRegen Inc
- Chong Kun Dang Pharmaceutical Corp
- Clarity Pharmaceuticals Pty Ltd
- Cloaked Therapeutics LLC
- Clovis Oncology Inc
- CMG Pharmaceutical Co Ltd
